HK Innoen and Tanabe Pharma Korea Sign Joint Promotion Agreement for "Badanem Tablets"
On March 10, HK Innoen announced that it had held a domestic joint promotion contract ceremony with Tanabe Pharma Korea for "Badanem Tablets" (ingredient name: vadadustat), a new drug for the treatment of renal anemia.
Under this agreement, the two companies will jointly conduct sales and marketing for Badanem Tablets in Korea. For medical institutions with over 100 beds, both companies will be responsible jointly, while HK Innoen will take charge exclusively of institutions with 100 beds or fewer. In addition, HK Innoen will have exclusive distribution rights for Badanem Tablets in Korea, leveraging its experience in selling renal disease products and its nationwide sales network. Through this, the company plans to actively target the market for chronic kidney disease patient treatments.
Employees of HK Inno.N and Tanabe Pharma Korea are taking a commemorative photo after the joint promotion contract ceremony for "Badanem Tablet". HK Inno.N
View original imageThe signing ceremony took place on February 23 at the Yeouido office of Tanabe Pharma Korea, located in FKI Tower, Yeongdeungpo-gu, Seoul. About 20 key executives and employees from both companies, including Dalwon Kwak, CEO of HK Innoen, and Wonkyu Lee, CEO of Tanabe Pharma Korea, attended the event and reaffirmed their commitment to cooperation.
Badanem Tablets is an oral medication used to treat anemia in adult patients with chronic kidney disease undergoing dialysis. It is a new drug in the class of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. The medication is available in two dosages, 150 mg and 300 mg, and is administered once daily. HK Innoen already has a range of renal disease-related products, including "Kremezin" (spherical carbon adsorbent for delaying dialysis) and "EPO" (an injectable treatment for renal anemia), and the addition of Badanem Tablets will further strengthen its portfolio.
Dalwon Kwak, CEO of HK Innoen, stated, "We expect to generate synergy effects with Badanem Tablets based on the renal disease product portfolio and robust sales infrastructure we have built. Through close collaboration between the two companies, we will strive to improve the quality of life for domestic patients with chronic kidney disease."
Wonkyu Lee, CEO of Tanabe Pharma Korea, said, "We are delighted to partner with HK Innoen, a company with expertise and outstanding sales capabilities. Through this collaboration, we expect Badanem Tablets to establish itself as a new treatment option for even more patients."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Badanem Tablets was originally developed by Akebia Therapeutics, and Tanabe Pharma holds the rights to distribute it in certain Asian countries, including Japan and Korea. In the United States, it was approved by the U.S. Food and Drug Administration (FDA) in 2024 under the product name "Vafseo" and, having demonstrated its efficacy and safety, has been prescribed since January 2025. In Korea, it received marketing authorization in March 2023 and, after being recognized for reimbursement adequacy in July last year, passed the Health Insurance Review & Assessment Service’s Reimbursement Standards Subcommittee.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.